Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shanghai Industrial Investment To Restructure Shanghai Pharmaceutical Group

This article was originally published in PharmAsia News

Executive Summary

Against the background of state-owned enterprises' restructuring, State-owned Assets Supervision & Administration Commission of Shanghai Municipal Government will transfer its 60 percent stake in Shanghai Pharmaceutical (Group) to Shanghai Industrial Investment (Holding). Shanghai Industrial Investment, the city's largest, most competitive and comprehensive conglomerate listed overseas, will soon conduct a due diligence check and formulate plan to reorganize Shanghai Pharmaceutical. According to sources, the relevant parties have reached an accord on bringing Shanghai Pharmaceutical public to pay off its debts, with surplus profit distributed to shareholders. The restructuring is expected to be a long-term process. (Click here for more - Chinese Language)

You may also be interested in...



Shanghai Pharmaceutical (Group) Begins Restructuring

Last year, Shanghai Industrial Investment acquired 60 percent stake in Shanghai Pharmaceutical (Group) and began a series of preparations for reorganization (PharmAsia News, June 30, 2008). In April, SII announced the restructuring of SPG and promised the release of a preliminary plan by June 30. However, SPG has already started its internal restructuring that will gradually transform its current 20-plus subsidiaries to independent corporate entities; one was officially declared as one this month. The move aims to make each firm a market player and raise operational efficiency. (Click here for more - Chinese Language)

‘Wrong Move’: Gottlieb Blasts Azar’s Perceived Regulatory Power Play Over FDA; HHS On Defense

The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”

US FDA Races To List Essential Medicines For Domestic Manufacture By White House Deadline

With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel